Every year, millions of retirees on Medicare Part D sail through the first few months of the year thinking their prescription costs are manageable. Then, around August or September, they get a letter from their plan. The language is bureaucratic, but the message is brutal: they have entered the coverage gap, also known as the donut hole. Suddenly, the copay they were used to disappears, replaced by a 25% coinsurance on brand-name drugs and 25% on generics. For a retiree taking two specialty medications for rheumatoid arthritis or a blood thinner, that shift can add $400 to $600 per month overnight. The donut hole is not a minor quirk — it is a systematic cost-shift that catches one in four Part D enrollees each year. And in 2025, because of the Inflation Reduction Act changes to drug pricing, the shape of that hole is changing. The gap is starting later, but the total out-of-pocket exposure for drugs in the catastrophic phase is actually going up. Retirees who do not plan for this will face surprise bills that drain their fixed income.
The old donut hole framework had three phases: deductible, initial coverage, gap, and catastrophic. In 2025, the structure remains the same, but the dollar thresholds have shifted. You pay 100% of drug costs until you hit the deductible (max $545 in 2025). Then you enter the initial coverage phase, where you pay a fixed copay or coinsurance (typically 25%) until your total drug costs — what you and your plan together spend — reach $5,030. That is the threshold for the coverage gap. In the gap, you pay 25% on brand-name drugs and 25% on generics. You stay in the gap until your out-of-pocket spending reaches $8,000. After that, you hit catastrophic coverage. In prior years, catastrophic coverage meant zero cost sharing. But in 2025, the Inflation Reduction Act eliminated the 5% coinsurance in the catastrophic phase entirely — for now. The trade-off is that the $8,000 out-of-pocket cap is now fixed, not sliding. So while the worst-case-scenario maximum is capped, reaching that cap means surviving the gap. For someone on two expensive brand-name drugs, the gap can be crossed in six weeks. For someone on mostly generics, the gap might stretch across five months. The key change: the deductible rose by $35, the initial coverage limit rose by $210, and the out-of-pocket threshold rose by $500. That means more spending before you reach relief.
The Inflation Reduction Act of 2022 was widely celebrated for capping insulin copays at $35 and allowing Medicare to negotiate drug prices. What got less attention: the law restructured the donut hole in a way that actually shifts more costs onto people with moderate drug expenses. Before 2024, once you left the gap, you paid 5% coinsurance in the catastrophic phase with no cap. The new law eliminated that 5% and set a hard out-of-pocket limit of $2,000 starting in 2025 for Part D. Wait — $2,000 out-of-pocket cap sounds great, right? Yes, but there is a catch. The $2,000 cap applies only to drugs covered under the Part D benefit. It does not apply to Part B drugs (like many infused biologics) or to drugs your plan does not cover. And here is the rub: the $2,000 cap is calculated based on what you pay at the pharmacy, not what your plan pays. In the gap, 25% coinsurance on a $12,000-a-year specialty drug means you pay $3,000 out of pocket before you hit the cap. If you have two such drugs, you hit the $2,000 cap quickly — but that cap means you stop paying after $2,000 total, not $2,000 per drug. So the Inflation Reduction Act actually helps people with extremely high drug costs. But for the retiree with moderate costs — say $4,000 in total annual drug spending — the donut hole now starts earlier relative to their income, and the 25% coinsurance in the gap is higher than the flat copays they paid in the initial coverage phase. A 2025 study from the Kaiser Family Foundation found that 14% of Part D enrollees with moderate drug costs will see their out-of-pocket spending increase by at least $800 compared to 2023 rules.
Let's walk through a concrete scenario. Margaret, 72, takes three maintenance drugs: a generic statin ($20/month), a generic beta blocker ($15/month), and a brand-name blood thinner Eliquis ($575/month retail). Her Part D plan has a $545 deductible, 25% coinsurance in initial coverage, and 25% coinsurance in the gap. She spends $545 in January on the Eliquis alone. She then pays 25% on Eliquis ($144/month) plus $35 for generics. By August, her total drug costs reach $5,030, so she enters the gap. In the gap, she still pays 25% on the brand Eliquis, and 25% on generics. That means $144 for Eliquis plus $9 for generics = $153/month. She stays in the gap until her out-of-pocket total reaches $2,000. She hit $545 from deductible, plus roughly $400 from initial coverage copays = $945. So she needs another $1,055 in out-of-pocket spending in the gap. At $153/month, that takes about seven months. But she entered the gap in August. That means she is still in the donut hole in December. Her total out-of-pocket for the year: $2,000. That is the cap. But if she were on two brand-name drugs, she would hit the cap in October and have zero costs for November and December. The trap: Margaret assumed her monthly costs would stay steady. They did not. Her out-of-pocket in the first half of 2025 averaged $180/month. In the second half, it jumped to $153/month for a shorter period — but the real shock was the deductible front-load in January. Many retirees do not budget for the $545 January hit, then get lulled into lower spring payments, then face the gap in fall. The total out-of-pocket of $2,000 is manageable if planned for. But the irregular cash flow causes credit card debt or skipped doses. A 2024 survey from the Senior Patients Alliance found that 22% of Part D enrollees who entered the donut hole in 2023 reported skipping doses or not filling a prescription.
Medicare.gov offers a Plan Finder tool that estimates your total annual out-of-pocket costs for each Part D plan in your area. Most retirees use it to compare monthly premiums. That is a mistake. You should use it to see which plan pushes your gap entry later in the year. Look for plans with lower initial coverage coinsurance on your specific drugs. If you take a brand-name drug, a plan that lists a $47 copay (tier 3) instead of 25% coinsurance could save you $500 in the gap. The Plan Finder allows you to enter your drug list and pharmacy. Run it in October during open enrollment. Sort plans by "estimated annual drug costs" — that number includes what you pay in all phases. Do not sort by monthly premium. A plan with a $20 higher premium but a $400 lower annual out-of-pocket is the better deal. Be aware that the Plan Finder uses list prices, not negotiated prices. So the estimate is a ceiling, not a guarantee. But it is the best data you have.
Your Part D plan is required to send you a notice when you reach the coverage gap. But that notice often arrives after the fact. You can proactively call your plan's customer service number in July and ask: "Based on my year-to-date drug spending, when do you estimate I will enter the coverage gap?" The representative can run a projection. If the gap start date is August or earlier, you have options. Ask whether your plan offers a gap-filler benefit. Some Medicare Advantage Prescription Drug (MAPD) plans provide reduced cost sharing in the gap for tier 1 and tier 2 drugs. Others do not. If your plan offers no gap coverage, consider switching during the next open enrollment. Also ask if any of your brand-name drugs have a manufacturer copay card. For drugs like Eliquis, Xarelto, or Januvia, the manufacturer offers copay assistance that counts toward your out-of-pocket. Using that card in the gap can knock $300 to $600 off your bill. The plan cannot prevent you from using a manufacturer card, though they often discourage it. Use it anyway.
In the coverage gap, you pay 25% coinsurance on generics. That is typically cheaper than brand-name coinsurance, but it can still be $10 to $30 per month. If your drug has no generic substitute, ask your doctor if a therapeutic alternative exists. For example, the generic version of Crestor (rosuvastatin) costs $9 per month in the gap. The branded version costs $45. That is a $432 annual savings. For drugs that do have generics, ask for a 90-day supply. Most Part D plans charge one coinsurance for a 90-day fill versus three for monthly fills. In the gap, that 90-day coinsurance is still 25% — but you pay it once instead of three times. The law requires plans to count mail-order and retail 90-day fills toward your out-of-pocket. The net effect: you hit the $2,000 cap faster because you push more spending into a single transaction. This is especially useful if you know you will enter the gap late in the year. Fill a 90-day brand-name prescription in October. That $360 hit (25% of $1,440) pushes you closer to the cap, and you might hit $2,000 in November, leaving December free.
The Low-Income Subsidy (LIS), also called Extra Help, helps people with limited income and assets pay Part D premiums, deductibles, and coinsurance. The income limit in 2025 is $22,590 for an individual ($30,660 for a couple). But many retirees assume they do not qualify because they have a pension or own a home. The asset limit is $17,220 for individuals ($34,360 for couples), and that excludes your primary home, one vehicle, and household goods. If you are close to the income limit, partial Extra Help is available. Partial Extra Help reduces your deductible to $104, limits your copays to $4.90 for generics and $12.15 for brand-name drugs, and eliminates the coverage gap entirely. Yes — if you have Extra Help, you never enter the donut hole. You pay flat copays year-round. The Social Security Administration processes applications. Many retirees overlook this because they think Extra Help is only for people on Medicaid. It is not. If your annual drug costs exceed $1,500, the application is worth the hour of paperwork. The National Council on Aging offers free assistance clinics in most states.
Here is a nuance most retirees miss: in the coverage gap, the 25% coinsurance applies to the full retail price of generics. But many generics have a retail price of $20 to $40 per month. That means you pay $5 to $10 in the gap — not nothing, but low enough that some retirees do not bother switching to mail-order. But here is the hack: if you fill a generic at a pharmacy that participates in a $4 generic program (like Walmart or some regional grocers), that pharmacy does not bill your Part D plan for that drug. You pay $4 out of pocket, and that $4 does count toward your out-of-pocket cap? Actually, no — if you do not run the drug through your Part D plan, the $4 payment does not count toward your $2,000 out-of-pocket limit. So do not do this for expensive drugs. But for $10 generics, the difference between $4 and $10 is trivial. However, if you run a $20 generic through your Part D plan, you pay $5 (25%) and that $5 counts toward your out-of-pocket. Over ten months, that is $50 counting toward the cap. If you pay $4 outside the plan, you save $1 per fill but lose $50 in progress toward the cap. For most people, the cap benefit is worth more than the $1 savings. Run the generic through your plan. Every dollar that counts toward the $2,000 cap matters if you are on the edge.
Planning for the donut hole is not complicated, but it requires a mid-year check that most retirees skip. Set a calendar reminder for July 1 each year. Call your plan. Get your projected gap entry date. Adjust your fills. If your income is under $22,590, apply for Extra Help before October. The $2,000 out-of-pocket cap in 2025 is a real safety net, but only if you understand the path it takes to get there. Do not let a letter in September be the first time you think about the gap.
Browse the latest reads across all four sections — published daily.
← Back to BestLifePulse